

COMMONWEALTH OF AUSTRALIA

Instrument number PB 74 of 2007

Amendment special arrangements under subsection 100(1) of the National Health Act 1953

I, STEPHEN DELLAR, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, make this instrument under subsection 100(1) of the *National Health Act 1953*.

Dated 6 Sept 2007

STEPHEN DELLAR

Assistant Secretary Pharmaceutical Evaluation Branch Department of Health and Ageing

<u>Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access</u> <u>Program</u>

1 Commencement

This instrument commences on 1 October 2007.

2 Amendment of PB 54 of 2007

Schedule 1 amends PB 54 of 2007.

Schedule 1 Amendments

(section 2)

[1] Schedule 1, omit item dealing with Calcium Folinate

[2] Schedule 1, omit item dealing with Cetuximab

and substitute:

Cetuximab	In compliance with authority procedures set out in paragraph 14:			
	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the Therapeutic Goods Administration-approved Product Information			
	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated			
	Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated			

[3] Schedule 1, after item dealing with Fluorouracil

insert in the columns in the order indicated:

Folinic acid	In respect of the tablet containing calcium folinate equivalent to 15 mg folinic acid:
	Antidote to folic acid antagonists
	In respect of the injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL, injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL and injection containing calcium folinate equivalent to 300 mg folinic acid in 30 mL:

[4] Schedule 2, omit items dealing with Calcium Folinate

[5] Schedule 2, after item dealing with Fluorouracil

insert in the columns in the order indicated:

Folinic acid	Tablet containing calcium folinate equivalent to 15 mg folinic acid	Oral	10		Leucovorin Calcium (Mayne Pharma Pty Ltd)
	Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL	Injection	5	5	Calcium Folinate Ebewe Leucovorin Calcium (Mayne Pharma Pty Ltd) Leucovorin Calcium (Pfizer Pty Limited)
	Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL	Injection	10	1	Calcium Folinate Ebewe Leucovorin Calcium (Pfizer Pty Limited)
	Injection containing calcium folinate equivalent to 300 mg folinic acid in 30 mL	Injection	4	1	Leucovorin Calcium (Mayne Pharma Pty Ltd)

[6] Schedule 2, after item dealing with Oxaliplatin in the form Powder for I.V. infusion 100 mg

insert in the columns in the order indicated:

Solution concentrate for I.V.	Injection	1	2	Eloxatin
infusion 200 mg in 40 mL				

[7] Schedule 4, omit item dealing with Calcium Folinate

and substitute:

Folinic acid	Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL	Leucovorin Calcium (Mayne Pharma Pty Ltd)	1	25.59	25.60
		Leucovorin Calcium (Pfizer Pty Limited)	10	205.31	205.51
	Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL	Calcium Folinate Ebewe	1	23.62	23.63